Acumen Pharmaceuticals Utilizes pTau217 Assay in Sabirnetug Phase 2 Alzheimer's Trial
核心洞察
Acumen Pharmaceuticals is using a validated plasma pTau217 assay to screen participants for its Phase 2 ALTITUDE-AD trial of sabirnetug in early Alzheimer's disease (搜索).
The pTau217 assay identifies individuals with Alzheimer's pathology, streamlining the enrollment process for the clinical trial.
Sabirnetug (ACU193) is a humanized monoclonal antibody targeting soluble amyloid beta oligomers (搜索), a toxic form of amyloid beta implicated in Alzheimer's.
Acumen Pharmaceuticals is employing a validated research-use plasma pTau217 assay to screen potential participants in its ongoing Phase 2 ALTITUDE-AD clinical trial of sabirnetug (ACU193) for early Alzheimer's disease (搜索). The company will present updated data on this screening approach at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference in Madrid, Spain.
pTau217 Assay as a Screening Tool
Phosphorylated tau at position 217 (pTau217) is a biomarker indicative of Alzheimer's disease (搜索) pathology. The plasma pTau217 assay serves as an initial screening tool to identify individuals who qualify for further amyloid testing, which determines their eligibility for the ALTITUDE-AD trial. This approach aims to enrich the trial population with individuals who are more likely to benefit from sabirnetug.
Sabirnetug (ACU193): Targeting Soluble Amyloid Beta Oligomers
Sabirnetug is a humanized monoclonal antibody specifically designed to target soluble amyloid beta oligomers (搜索) (AβOs), which are considered highly toxic and pathogenic forms of Aβ. These oligomers have been shown to bind to neurons, inhibit synaptic function, and induce neurodegeneration. By selectively targeting soluble AβOs, sabirnetug aims to address the underlying cause of neurodegeneration in Alzheimer's disease (搜索). The U.S. Food and Drug Administration has granted Fast Track designation to sabirnetug for the treatment of early Alzheimer's disease.
ALTITUDE-AD Trial Details
ALTITUDE-AD is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial initiated in 2024. It is designed to evaluate the efficacy and safety of sabirnetug infusions, administered once every four weeks, in slowing cognitive and functional decline compared to placebo in participants with early Alzheimer's disease (搜索). The study plans to enroll approximately 540 individuals with early Alzheimer's disease (mild cognitive impairment or mild dementia due to AD). The trial is ongoing at multiple sites in the United States, Canada, the UK, and the European Union (NCT06335173).
Alzheimer's Disease Context
Alzheimer's disease (搜索) affects millions worldwide, with a significant unmet need for effective therapies that can modify the course of the disease. Current treatments primarily address symptoms, but do not halt or reverse the underlying neurodegenerative process. The focus on targeting soluble amyloid beta oligomers (搜索) represents a promising approach to address the disease's root cause.